Close Menu

Biocartis

NEW YORK (GenomeWeb) – Biocartis today announced it has obtained CE-IVD marking for and commercially launched the Idylla molecular diagnostics platform and BRAF Mutation Test.

NEW YORK (GenomeWeb) – Biocartis announced today that it has raised €64.5 million ($84 million) in a round of private financing.

NEW YORK (GenomeWeb) – The Flemish Government has awarded Biocartis a €1.7 million ($2.3 million) grant to build out the capabilities of the company's Idylla molecular diagnostics platform, Biocartis said today.

NEW YORK (GenomeWeb) – Molecular diagnostics firm Biocartis and Abbott today announced a collaboration to develop and commercialize companion diagnostic tests for use on Biocartis' Idylla system.

NEW YORK (GenomeWeb News) – Invetech will support the development and manufacture of Biocartis' multiplex platform for biomarker analysis under an agreement announced today.

NEW YORK (GenomeWeb News) – Biocartis today said that it has exclusively licensed from life science research institute VIB a panel of microsatellite instability biomarkers for several cancers, including colorectal cancer, which it plans to use in developing a molecular diagnostic assay.

NEW YORK (GenomeWeb News) – Biocartis and BioMérieux on Thursday announced a mutual agreement to end their alliance to develop and commercialize the integrated molecular biology system called Idylla.

NEW YORK (GenomeWeb News) – Swiss molecular diagnostics firm Biocartis said today that it has raised €30 million ($40.5 million) in a Series E equity financing.

This story has been updated from a previous version to include information about Biocartis' newly branded MDx platform and AACR presentation.

NEW YORK (GenomeWeb News) – Molecular diagnostics firm Biocartis today announced that it has licensed from Hospital del Mar in Spain the rights to an EGFR biomarker for colon cancer.

Pages

NPR says the explosion and fire earlier this week at a Russian lab that stores dangerous pathogens revives the question of whether such samples should be kept.

According to Wired, Nebula Genomics is providing a way for people to get their genomes sequenced anonymously.

A 26-year-old woman tells Cosmopolitan about learning her APOE status at a young age.

In Science journals this week: a functional genomic screen uncovers drug combination that increases KRAS inhibitor efficacy in aggressive lung cancer, and more.